Litai Zhiyao
Designs peptide drugs with generative models. It runs a platform-plus-pipeline model, taking partner work now and building its own oncology, autoimmune and metabolic programmes; its L2F backers describe the design space as extending to non-natural and mirror-image D-peptides.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2026-10-10SeedRound
nearly CNY 50M
For: compute rental, core pipeline R&D, patent filings, hiring and day-to-day operations
Models and platformHiring
The company announced it through PEdaily with its founder and both named investors quoted. The release names no lead (the three investors are described as co-investing), and the third, an industry investor, is not named. No valuation. Lighthouse Capital acted as exclusive financial adviser rather than as an investor, but the two are related: L2F, listed here as a participant, is Lighthouse Capital's own seed fund, and Xuanle Zheng is the firm's founder and the fund's founding partner. No company website and no English company name were found, so the name here is the pinyin of the Chinese one.
iFlytek VenturesLighthouse Founders' Fund
On the deal: Jingming Xu (Chair, iFlytek Ventures); Xuanle Zheng (Founding Partner, Lighthouse Founders' Fund); Xuequn Huang (Executive Director, Lighthouse Founders' Fund)
Advisers: Lighthouse Capital (exclusive financial adviser)
Announced by the company · news.pedaily.cn ↗On the timeline →
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.